BERKELEY HEIGHTS, N.J., Oct. 28, 2009 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company") announced upcoming corporate events that will take place during November and December 2009.

Release of Third Quarter 2009 Financial Results and Conference Call - Tuesday November 3

Cyclacel will announce its third quarter 2009 financial results on Tuesday, November 3, 2009. The Company will host a conference call and live webcast at 4:30 p.m. Eastern on the same day.

Conference call information:

US/Canada call: (877) 493-9121/ international call: (973) 582-2750

US/Canada archive: (800) 642-1687 / international archive: (706) 645-9291

Code for live and archived conference call is 37927625.

For the live and archived webcast, please visit the Corporate Presentations page on the Cyclacel website at www.cyclacel.com. The webcast will be archived for 90 days and the audio replay for 7 days.

Merriman Curhan Ford Investor Summit 2009 - Tuesday, November 10

Spiro Rombotis, President and CEO, will present an overview of the Company at the Merriman Investor Summit 2009 at the Sofitel Hotel in New York. The presentation will take place on Tuesday, November 10 at 1:20 p.m. Eastern.

Lazard Capital Markets 6th Annual Healthcare Conference - Tuesday, November 17

Spiro Rombotis, President and CEO, will present an overview of the Company at the Lazard Capital Markets 6th Annual Healthcare Conference at The St. Regis Hotel in New York. The presentation will take place on Tuesday, November 17 at 9:55 a.m. Eastern.

The New York Society of Security Analysts 13th Annual NYSSA Biotech & Specialty Pharmaceuticals Industry Conference - Tuesday, December 1

Spiro Rombotis, President and CEO, will present an overview of the Company at The New York Society of Security Analysts' 13th Annual NYSSA Biotech & Specialty Pharmaceuticals Industry Conference at the NYSSA's Conference Center, 1177 6th Avenue, New York. The presentation will take place on Tuesday, December 1.

About Cyclacel Pharmaceuticals, Inc.

Cyclacel is a diversified biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Sapacitabine, a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and lung cancer and in Phase 1 in combination with seliciclib. Seliciclib, a CDK (cyclin dependent kinase) inhibitor, is in Phase 2 for the treatment of lung and nasopharyngeal cancer. CYC116, an Aurora kinase and VEGFR2 inhibitor, is in Phase 1 in patients with solid tumors.